title: Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence.
abstract: Latent tuberculosis infection (LTBI) and human immunodeficiency virus (HIV)-coinfection are challenges in the control of tuberculosis transmission. We aimed to assess and summarize evidence available in the literature regarding the treatment of LTBI in both the general and HIV-positive population, in order to support decision making by the Brazilian Tuberculosis Control Program for LTBI chemoprophylaxis. We searched MEDLINE, Cochrane Library, Centre for Reviews and Dissemination, Embase, LILACS, SciELO, Trip database, National Guideline Clearinghouse, and the Brazilian Theses Repository to identify systematic reviews, randomized clinical trials, clinical guidelines, evidence-based synopses, reports of health technology assessment agencies, and theses that investigated rifapentine and isoniazid combination compared to isoniazid monotherapy. We assessed the quality of evidence from randomized clinical trials using the Jadad Scale and recommendations from other evidence sources using the Grading of Recommendations, Assessment, Development, and Evaluations approach. The available evidence suggests that there are no differences between rifapentine + isoniazid short-course treatment and the standard 6-month isoniazid therapy in reducing active tuberculosis incidence or death. Adherence was better with directly observed rifapentine therapy compared to self-administered isoniazid. The quality of evidence obtained was moderate, and on the basis of this evidence, rifapentine is recommended by one guideline. Available evidence assessment considering the perspective of higher adherence rates, lower costs, and local peculiarity context might support rifapentine use for LTBI in the general or HIV-positive populations. Since novel trials are ongoing, further studies should include patients on antiretroviral therapy.
authors.affiliation: Departamento de Saúde Coletiva, Faculdade de Ciências da Saúde, Universidade de Brasília, Brasília, Distrito Federal, Brazil.
authors.forename: Júlia Souza
authors.initials: JS
authors.lastname: Vidal
authors.affiliation: Departamento de Saúde Coletiva, Faculdade de Medicina, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.
authors.forename: Marcus Tolentino
authors.initials: MT
authors.lastname: Silva
authors.affiliation: Departamento de Saúde Coletiva, Faculdade de Ciências da Saúde, Universidade de Brasília, Brasília, Distrito Federal, Brazil.
authors.forename: Mauro Niskier
authors.initials: MN
authors.lastname: Sanchez
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000995:Antitubercular Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage*; D055985:Latent Tuberculosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012293:Rifampin / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin; C018421:rifapentine